Impact of 1‐year treatment with dupilumab on work productivity in Japanese patients with atopic dermatitis

Abstract Atopic dermatitis (AD) places a burden on work productivity. Recently, dupilumab was approved for AD, but its impact on work productivity in Japanese patients has not been reported. Furthermore, data on the effect of long‐term treatment with dupilumab on work productivity are limited. We investigated the work productivity and activity in Japanese patients with moderate‐to‐severe AD, utilizing the Japanese version of the Work Productivity and Activity Impairment (WPAI‐AD‐Japan) questionnaire. Furthermore, we examined the impact of dupilumab on work productivity. Adult moderate‐to‐severe AD patients treated with dupilumab for more than 12 months from March 2020 to June 2022 who filled out the WPAI‐AD‐Japan questionnaire were included. Twenty‐eight adult AD patients were analysed. Absenteeism was low (mean: 5.3%), but presenteeism, work productivity loss and activity impairment were high (36.8%, 39.7%, 48.9%, respectively). Significant positive correlations were observed between work productivity loss and visual analogue scale (VAS) score of pruritus and between activity impairment and dermatology life quality index (DLQI). Dupilumab treatment significantly reduced presenteeism, work productivity loss and activity impairment at both 6 and 12 months. The extent of their amelioration was numerically higher at 12 months than at 6 months. The reduction rates in presenteeism, work productivity loss and activity impairment were positively correlated with the reduction rates in DLQI and VAS score of pruritus at 12 months. Dupilumab improved work productivity in Japanese AD patients. Long‐term remission of pruritus and improved quality of life are important for comprehensive improvement of work productivity.